JPRN-UMIN000005180已完成2 期
phase II study of panitumumab with irinotecan as third-line treatment for advanced colorectal cancer patients - phase II study of panitumumab with irinotecan as third-line treatment for advanced colorectal cancer patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Advanced pleural effusion, ascites 2) CNS metastases 3) Infection 4) Diarrhea (watery stool) 5) Heart disease as a clinical problem 6) Severe complications (intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, it is difficult to control diabetes, heart failure, kidney failure, liver failure etc.) 7) Active double cancer 8) Severe mental disorder 9) Irinotecan, oxaliplatin, panitumumab history of hypersensitivity to 10) Treatment with atazanavir sulfate 11) Pregnant and lacting women 12) Severe drug allergy 13) Judged unfit to by doctors in this study
研究者
相似试验
招募中
2 期
A Phase II trial of Panitumumab with irinotecan/S-1(IRIS) as 1st-line chemotherapy for KRAS wild type metastatic colorectal cancerKRAS wild type metastatic colorectal cancerJPRN-UMIN000008496Tohoku-Six Universities Research Group by Experts(T-SURGE)45
进行中（未招募）
1 期
A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab PlusAMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to PanitumumabMetastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2008-004752-77-FRAmgen Inc76
进行中（未招募）
1 期
A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab - 20070820Metastatic colorectal cancer expressing wild type (wt) KRAS and refractory to irinotecan- and oxaliplatin-containing regimens, or refractory to oxaliplatin-containing regimens.MedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2008-004752-77-ITAmgen Inc.76
进行中（未招募）
不适用
Ph2 Biomarker (Mechanism of K-ras Dependency) in Wt KRAS Metastatic Colorectal Cancer PatientsMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2008-004752-77-DEAmgen Inc75
进行中（未招募）
1 期
Ph2 Biomarker (Mechanism of K-ras Dependency) in Wt KRAS Metastatic Colorectal Cancer PatientsEUCTR2008-004752-77-BEAmgen Inc75